Atlas Trials

T-DM1 Combined With CDK4/6 Inhibitor Ribociclib

Clinical trial NCT06481956 · ENROLLING_BY_INVITATION

Trial details

NCT number
NCT06481956
Sponsor
Zheng Yabing
Status
ENROLLING_BY_INVITATION
Phase
Phase 2
Study type
INTERVENTIONAL
HER2-positive Advanced Breast Cancer
Start date
2023-10-25
Primary completion
2027-01-10
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.